The application of functional genomics to Alzheimer's disease

Pharmacogenomics

Volumn 4, Issue 5, 2003, Pages 597-621

  Cacabelos, Ramón ^a  

^a Centro de Investigacion Biomedica EuroEspes   (Spain)

Author keywords

Alzheimer's disease; APOE; CYP2D6; Functional genomics; Genetic variation; Genetics; Genomics; Genotype phenotype correlations; Pharmacogenetics; Pharmacogenomics

Indexed keywords

AMITRIPTYLINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHLORPROMAZINE; CITICOLINE; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2D6; DESIPRAMINE; DONEPEZIL; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MIANSERIN; MINAPRINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PIRACETAM; POLYPODIUM LEUCOTOMOS EXTRACT; REBOXETINE; RISPERIDONE; TACRINE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ALZHEIMER DISEASE; APOPTOSIS; BLOOD PRESSURE; BRAIN ATROPHY; BRAIN PERFUSION; COGNITION; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAM; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIPID METABOLISM; LIPOPROTEIN SECRETION; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BRAIN; CYTOCHROME P-450 CYP2D6; GENOMICS; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

POLYPODIUM LEUCOTOMOS;

EID: 0141851356     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/phgs.4.5.597.23795     Document Type: Review

References (117)

1. Cacabelos R: Handbook of Neurogeriatrics. Alzheimer's disease and Other Dementias. Epidemiology and Genetics. Masson, Barcelona, Spain (1999).
2. Cacabelos R: Psychogeriatric research. A conceptual introduction to geriatric neuroscience. Psychogeriatrics 1, 158-188 (2001).
3. Wimo A, Jönsson B, Karlsson G, Winblad B: Health Economics of Dementia. Wiley, Chichester, UK (1998).
4. Giacobini E: Cholinesterases and Cholinesterase Inhibitors. Martin Dunitz, London, UK (2000).
5. Cacabelos R: Pharmacogenomics in Alzheimer's disease. Min. Rev. Med. Chem. 2, 59-84 (2002).
6. Cacabelos R: Pharmacogenomics for the treatment of dementia. Ann. Med. 34, 357-379 (2002).
7. Frank RA, Galsko D, Hampel H et al.: Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24, 521-536 (2003).
8. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81,741-766 (2001).
9. Cacabelos R: Dementia. In: Clinical Psychiatry. Jobe TH, Gaviria M, Kovilparambil A (Eds.), Blackwell Science, Massachusetts, USA, 73-122 (1997).
10. Cacabelos R: Diagnosis of Alzheimer's disease: defining genetic profiles (genotype versus phenotype). Acta Neurol. Scand. 165, 72-84 (1996).
11. De la Torre JC, Stefano GB: Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res. Rev 34, 119-136 (2000).
12. Cacabelos R, Fernández-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y: Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res. (In Press).
13. Cacabelos R, Alvarez XA, Lombardi V et al.: Pharmacological treatment of Alzheimer's disease: from phychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 36, 415-499 (2000).
14. Guttmacher AE, Collins FS: Genome medicine-A primer. N. Engl. J. Med. 347, 1512-1520 (2002).
15. Cantor CR, Smith CL: Genomics. The Science and Technology behind the Human Genome Project. Wiley, New York, USA (1999).
16. Mount DW: Bioinformatics. Sequence and Genome Analysis. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA (2001).
17. Analysis of Multifactorial Disease. Bishop T, Sham P (Eds), BIOS Scientific Publishers, Oxford, UK (2000).
18. Hariri AR, Weinberger DR: Imaging genomics. Br. Med. Bull. 65, 259-270 (2003).
19. Hardy J, Gwinn-Hardy K: Genetic classification of primary degenerative disease. Science 282, 1075-1079 (1998).
20. Tanzi RE, Kovacs DM, Kim TW et al.: The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3, 159-168 (1996).
21. Schellenberg GD, D'Souza I, Poorkaj P: The genetics of Alzheimer's disease. Curr. Psychiatry Rep. 2, 158-164 (2000).
22. St. George-Hyslop PH: Genetic factors in the genesis of Alzheimer's disease. Ann. NY Acad. Sci. 924, 1-7 (2000).
23. Price DL, Sisodia SS: Mutant genes in familial Alzheimer's disease and transgenic models. Ann. Rev. Neurosci. 21, 479-505 (1998).
24. Van Gassen G, Annaert W: Amyloid, presenilins, and Alzheimer's disease. Neuroscientist 9, 117-126 (2003).
25. Mesa MD, Fernández-Novoa L, Cacabelos R: Association of genetic risk factors in Alzheimer's disease. Ann. Psychiatry 7, 35-45 (1999).
26. Greeve I, Hermans-Borgmeyer I, Brellinger C et al.: The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J. Neurosci. 20, 7345-7352 (2000).
27. Prince JA, Feuk L, Swayer SL et al.: Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur. J. Genet. 9, 437-444 (2001).
28. Bertram L, Blacker D, Crystal A et al.: Candidate genes showing no evidence for association or linkage with Alzheimer's disease. Exp. Gerontol. 35, 1353-1361 (2000).
29. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genetics 33, 177-182 (2003).
30. Ioannidis JPA, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG: Genetic associations in large versus small studies: an empirical assessment. Lancet 361, 567-571 (2003).
31. Colhoun HM, McKeigue PM, Smith GD: Problems reporting genetic associations with complex outcomes. Lancet 361, 865-872 (2003).
32. Cacabelos R, Fernández-Novoa L, Lombardi V, Takeda M: Genetic variation and pharmacogenomics in Alzheimer's disease. Psychiat Neurol Jap 105, 47-67 (2003).
33. Cacabelos R: Pharmacogenomics in Alzheimer's disease. Drug News Perspect. 13, 252-254 (2000).
34. Cacabelos R, Alvarez A, Fernández-Novoa L, Lombardi VRM: A pharmacogenomic approach to Alzheimer's disease. Acta Neurol. Scand 176, 12-19 (2000).
35. Jazwinska EC: Exploiting human genetic variation in drug discovery and development. Drug Dis. Today 6, 198-205 (2001).
36. Johnson GCL, Todd JA: Strategies in complex disease mapping. Curr. Opin. Genet. Dev. 10, 330-334 (2000).
37. Foster MW, Sharp RR: Race, ethnicity, and genomics: social classifications as proxies of biological heterogeneity. Genome Res. 12, 844-850 (2002).
38. Patil N, Berno AJ, Hinds DA et al.: Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 294, 1719-1723 (2001).
39. Oleksiak MF, Curchill GA, Crawford DL: Variation in gene expression within and among natural populations. Nat. Genetics 32, 261-266 (2002).
40. Jordan IK, Rogozin IB, Wolf YI, Koonin EV: Essential genes are more evolutionarily conserved than are nonessential genes in bacteria. Genome Res. 12, 962-968 (2002).
41. Raff MC, Whitmore AV, Finn JT. Axonal self-destruction and neurodegeneration. Science 296, 868-871 (2002).
42. Brown VM, Ossadtchi A, Khan AH, Cherry SR, Leahy RM, Smith DJ: High-throughput imaging of brain gene expression. Genome Res. 12, 244-254 (2002).
43. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP: In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat. Genetics 33, 469-475 (2003).
44. Eaves IA, Wicker LS, Ghandour G et al.: Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: The NOD mouse model of Type 1 diabetes. Genome Res. 12, 232-244 (2002).
45. Saunders AM, Trowers MK, Shimkets RA et al.: The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochem. Biophys. Acta 1502, 85-94 (2000).
46. Posthuma D, De Geus EJC, Baaré WFC, Pol HEH, Kahn RS, Boomsma DI: The association between brain volume and intelligence is of genetic origin. Nat. Neurosci. 5, 83-84 (2002).
47. Thompson PM, Cannon TD, Narr KL et al.: Genetic influences on brain structure. Nat. Neurosci. 4, 1253-1258 (2001).
48. Valk J, Barkhof F, Scheltens P: Magnetic Resonance in Dementia. Springer, Berlin, Germany (2002).
49. Etcheverría I, Amado L, Pichel V, Cacabelos R: Differential brain atrophy profile associated with the APOE genotype in the Spanish population 6th International Conference on Stroke and 3rd Conference of the Mediterranean Stroke Society, Monte Carlo, Monaco, 47 (2003).
50. Alvarez XA, Mouzo R, Pichel V et al.: Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity, and cerebral perfusion. Meth. Find. Exp. Clin. Pharmacol. 21, 633-644 (1999).
51. Alvarez XA, Pichel V, Pérez P et al.: Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth. Find. Exp. Clin. Pharmacol. 22, 585-594 (2000).
52. Etcheverría I, Amado L, Pichel V, Cacabelos R: Age- and APOE-dependent cerebrovascular changes in the Spanish population 6th International Conference on Stroke and 3rd Conference of the Mediterranean Stroke Society, Monte Carlo, Monaco, 32 (2003).
53. Papassotiropoulos A, Streffer JR, Tsolaki M et al.: Increased brain β-amyloid load, phosphorylated tau, and risk of Alzheimer's disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60, 29-35 (2003).
54. Puglielli L, Tanzi RE, Kovacs DM: Alzheimer's disease : the cholesterol connection. Nat. Neurosci. 6, 345-351 (2003).
55. De la Torre JC: Alzheimer's disease as a vascular disorder. Stroke 33, 1152-1162 (2002).
56. De la Torre JC: Vascular basis of Alzheimer's pathogenesis. Ann. NY Acad. Sci. 977, 196-215 (2002)
57. Fernández-Novoa L, Cacabelos R: Histamine function in brain disorders. Behav. Brain Res. 124, 213-233 (2001).
58. Cacabelos R: The histamine-cytokine network in Alzheimer's disease: Etiopathogenic and pharmacogenomic implications. In: Mapping Progress of Alzheimer's and Parkinson's diseases. Advances in Behavioral Biology (Vol 51). Mizuno Y, Fisher A, Hanin I (Eds), Pergamon Press, New York, USA 59-64 (2002).
59. Williamson KS, Gabbita SP, Mou S et al.: The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 6, 221-227 (2002).
60. Butterfield DA, Castegna A, Lauderback CM, Drake J: Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 23, 655-664 (2002).
61. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA: Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80, 91-100 (2002).
62. Colton CA, Brown CM, Cook D et al.: APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol. Aging 23, 777-785 (2002).
63. Haas J, Storch-Hagenlocher B, Biessmann A, Wildemann B: Inducible nitric oxide synthase and argininosuccinate synthase: coinduction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci. Lett. 322, 121-125 (2002).
64. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sci. 962, 318-331 (2002).
65. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
66. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
67. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 360, 1155-1162 (2002).
68. Isaza CA, Henao J, López AM, Cacabelos R: Isolation, sequence and gentyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol. 22, 695-705 (2000).
69. Isaza C, Henao J, Fernández-Novoa L, Cacabelos R: The drug metabolizer CYP2D6 in Alzheimer's disease therapy. 6th International Congress on Alzheimer's and Parkinson's diseases, Seville, Spain, 56 (2003).
70. Poirier J: Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J. Psychiat. Neurosci. 24, 147-153 (1999).
71. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50, 669-677 (1998).
72. Rigaud AS, Traykov L, Caputo L et al.: The apolipoprotein E epsilon 4 allele and the response to tacrine therapy in Alzheimer's disease. Eur. J. Neurol. 7, 255-258 (2000).
73. Cacabelos R, Fernández-Novoa L, Pichel V, Lombardi V, Kubota Y, Takeda M: Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Molecular Neurobiology of Alzheimer's disease and Related Disorders. Takeda M (Ed.), Karger, Tokyo, Japan (In Press).
74. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
75. Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA: Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol. Aging 22, 131-146 (2001).
76. Wong PC, Cai H, Borchelt DR, Price DL: Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5, 633-639 (2002).
77. Driscoll M, Gerstbrein B: Dying for a cause: Invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 4, 181-194 (2003).
78. Atkinson J: Cerebrovascular structure and dementia: new drug targets. Trend Pharmacol. Sci. 22, 630-635 (2001).
79. Stoll M, Cowley AW, Tonellato PJ et al.: A genomic-systems biology map for cardiovascular function. Science 294,1723-1726 (2001).
80. Scott WK, Nance MA, Watts RL et al.: Complete genomic scree in Parkinson's disease. Evidence for multiple genes. JAMA 286, 2239-2244 (2001).
81. Ben-Shahar Y, Robichon A, Sokolowski MB, Robinson GE: Influence of gene action across different time scales on behavior. Science 296, 741-744 (2002).
82. Plomin R, Kosslyn SM: Genes, brain and cognition. Nat. Neurosci. 4, 1153-1155 (2001).
83. Ohno M, Frankland PW, Chen AP, Costa RM, Silva AJ: Inducible, pharmacogenetic approaches to the study of learning and memory. Nat. Neurosci. 4, 1238-1243 (2001).
84. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
85. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trend Pharmacol. Sci. 22, 298-305 (2001).
86. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potencial role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA 286, 2270-2279 (2001).
87. Norton RM: Clinical pharmacogenomics: applications in pharmaceutical R&D. DDT 6, 180-185 (2001).
88. McCarthy JJ, Hilfiker R: The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat. Biotech. 18, 505-508 (2000).
89. Janson CG, McPhee SWJ, Leone P, Freese A, During MJ: Viral-based gene transfer to the mammalian CNS for functional genomic studies. Trend Neurosci. 24, 706-712 (2001).
90. Weiss KM, Terwilliger JD: How many diseases does it take to map a gene with SNPs? Nat. Genet. 26, 151-157 (2000).
91. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289, 2094-2103 (2003).
92. Shoji M, Matsubara E, Murakani T et al.: Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol. Aging 23, 363-370 (2002).
93. Petronis A: Human morbid genetics revisited: relevance of epigenetics. Trend. Genet. 17, 142-146 (2001).
94. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33, 245-254 (2003).
95. Soto C: Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49-60 (2003).
96. Gaudet F, Hodgson JG, Eden A et al.: Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492 (2003).
97. Rutherford SL: Between genotype and phenotype: Protein chaperones and evolvability. Nat. Rev. Genet. 4, 263-274 (2003).
98. Kayed R, Head E, Thompson JL et al.: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
99. Lomas DA, Carrell RW: Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3, 759-768 (2002).
100. Bucciantini M, Giannoni E, Chiti F et al.: Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 (2002).
101. Lewis J, Dickson DW, Lin W-L et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001).
102. Götz J: Tau and transgenic animal models. Brain Res. Rev. 35, 266-286 (2001).
103. Pawson T, Nash P: Assembly of cell regulatory systems through protein interaction domains. Science 300, 445-453 (2003).
104. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet. 33, 228-237 (2003).
105. Patterson SD, Aebersold RH: Proteomics: the first decade and beyond. Nat. Genet. 33, 311-323 (2003).
106. Kanehisa M, Bork P: Bioinformatics in the post-sequence era. Nat. Genet. 33, 305-310 (2003).
107. Geschwind DH: DNA microarrays: translation of the genome from laboratory to clinic. Lancet Neurol. 2, 275-282 (2003).
108. Chicurel ME, Dalma-Weiszhausz DD: Microarrays in pharmacogenomcis-advances and future promise. Pharmacogenomcis 3, 589-601 (2002).
109. Dumas TC, Sapolsky RM: Gene therapy against neurological insults: sparing neurons versus sparing function. Trend Neurosci. 24, 695-700 (2001).
110. Gozes I: Neuroprotective peptide drug delivery and development: potential new therapeutics. Trend Neurosci. 24, 700-705 (2001).
111. Liotta LA, Kohn EC, Petriconi EF: Clinical proteomics. Personalized molecular medicine. JAMA 286, 2211-2214 (2001).
112. Jiang Y, Jahagirdar BN, Reinhardt RL et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 41-49 (2002).
113. Song H, Stevens CF, Gage FH: Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nature Neurosci. 5, 438-445 (2002).
114. King HC, Sinha AA: Gene expression profile analysis by DNA microarrays. Promise and pitfalls. JAMA 286, 2280-2288 (2001).
115. Subramanian G, Adams MD, Venter JC, Broder S: Implications of the human genome for understanding human biology and medicine. JAMA 286, 2296-2307 (2001).
116. Mandel S, Weinreb O, Youdim MBH: Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trend Pharmacol. Sci. 24, 184-191 (2003).
117. Merikangas KR, Risch N: Will the genomics revolution revolutionize psychiatry? Am. J. Psychiatry 160, 625-635 (2003).